Search company, investor...

Founded Year



Series D | Alive

Total Raised


Last Raised

$9.22M | 2 yrs ago

About Ybrain

Ybrain is a company that focuses on the development of medical devices for the treatment of neuropsychiatric illnesses, operating within the healthcare and technology sectors. The company's main offerings include wearable devices that utilize neuroscience to measure and treat conditions such as Major Depressive Disorder. These devices provide a comprehensive mental health solution that can be used in a home setting. It was founded in 2013 and is based in Republic of Korea, South Korea.

Headquarters Location

#228, 54, Changeop-ro Sujeong-gu, Seongnam-si, Gyeonggi-do

Republic of Korea, 13449,

South Korea


Ybrain's Product Videos

Ybrain's Products & Differentiators


    Electroceutical platform


Expert Collections containing Ybrain

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ybrain is included in 4 Expert Collections, including Conference Exhibitors.


Conference Exhibitors

6,062 items

Companies that will be exhibiting at CES 2018


Smart Home & Consumer Electronics

1,234 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Mental Health Tech

742 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

Ybrain Patents

Ybrain has filed 30 patents.

The 3 most popular patent topics include:

  • neurophysiology
  • electrotherapy
  • neurotechnology
patents chart

Application Date

Grant Date


Related Topics




Neurophysiology, Electrotherapy, Neurotechnology, Electrophysiology, Cerebral cortex


Application Date


Grant Date



Related Topics

Neurophysiology, Electrotherapy, Neurotechnology, Electrophysiology, Cerebral cortex



Latest Ybrain News

Ybrain's MINDD STIM proves effective in improving depression-based attentional bias

Sep 6, 2023

닫기 Ybrain, a company specializing in mental health therapeutics, said on Wednesday that a clinical trial conducted in the U.S. using its depression electroceutical, MINDD STIM, showed efficacy in improving immediate depression symptoms. Ybrain, a company specializing in mental health therapeutics, said on Wednesday that a clinical trial conducted in the U.S. using its depression electroceutical, MINDD STIM, showed efficacy in improving immediate depression symptoms. (Credit: Ybrain) Depressed patients have difficulty interpreting other people's emotional expressions, which can lead to high rates of recognition errors. This has been linked to increased activity in the amygdala and decreased activity in the left frontal lobe, which is responsible for processing emotional information, leading to an attentional bias that focuses on negative stimuli. The research team at NYU Langone's Department of Neurology designed a clinical trial to measure how well depressed patients can recognize facial emotions quickly and accurately, and how emotional changes affect their attention using MINDD STIM transcranial direct current stimulation (tDCS). The trial ran for six months from June to December last year and 20 women with mild to moderate depression were compared to 21 healthy women to determine the speed of cognitive response to immediate facial expression recognition changes before and after tDCS application to the left frontal lobe. The diagram shows the visual search task example trial presented to patients in the clinical trial to identify the target face (different sex), using the arrow on the keyboard. when presented with sad expressions, neutral expressions, and distractor (Sad and Neutral) expressions. The clinical trial found that a single use of MINDD STIM improved the negative attentional bias of depressed patients, and they also reported feeling less depressed and happier after treatment. In particular, the participants with depression differed from the control group in emotional processing speed and accuracy in identifying sad stimuli before tDCS treatment. This showed that depressed patients had a concomitant deterioration in attention that allowed them to recognize negative stimuli more quickly but with poorer accuracy. In response to the tDCS treatment, the participants with depression became significantly faster on the distractor condition, suggesting a specific reduction in bias toward negative emotional information. Additionally, the depressed group also had significant improvements in self-reported mood including increased happy, decreased sad and anxious mood. "It is very encouraging to see the immediate improvement in depressive attentional bias of MINDD STIM on the global stage through the U.S. clinical trial," said Ybrain CEO Lee Ki-won. "We expect that the face recognition visual search task utilized in this trial will serve as an excellent indicator of MINDD STIM’s effectiveness in treating depression." The results of the study were published in the international journal Neuromodulation on Aug. 20.

Ybrain Frequently Asked Questions (FAQ)

  • When was Ybrain founded?

    Ybrain was founded in 2013.

  • Where is Ybrain's headquarters?

    Ybrain's headquarters is located at #228, 54, Changeop-ro, Republic of Korea.

  • What is Ybrain's latest funding round?

    Ybrain's latest funding round is Series D.

  • How much did Ybrain raise?

    Ybrain raised a total of $24.24M.

  • Who are the investors of Ybrain?

    Investors of Ybrain include KT&G, Ceragem, InterVest, NEOFECT, G.N. Tech Venture Capital and 12 more.

  • Who are Ybrain's competitors?

    Competitors of Ybrain include Calm and 5 more.

  • What products does Ybrain offer?

    Ybrain's products include MINDD STIM+ and 4 more.


Compare Ybrain to Competitors

Journey Logo

Journey provides online and offline meditation services. It offers a preventative mental health solution. Its instructors teach live group well-being classes in a simple, approachable way to local communities. It was founded in 2015 and is based in New York, New York.

Unmind Logo

Unmind operates as a workplace mental health platform. The platform offers scientifically-backed tools and training for healthier, happier, more human organizations. Logo provides a digital platform sending users reminders to take breaks and features breath work, mindfulness, and other break reminders. It detects stress and suggests a short one to three-minute break, guided meditation, breathing exercise, or seated movement The company was founded in 2018 and is based in New York, New York.

Litesprite Logo

Litesprite operates as a game development company. It develops games that combine medical treatment and the engagement of mobile gaming to help patients proactively manage chronic health conditions such as stress, anxiety, and depression. The company was founded in 2013 and is based in Bellevue, Washington.

Nguvu Health Logo
Nguvu Health

Nguvu Health develops a space to get help from mental health professionals. It offers a mobile application in which users can speak and be connected to a qualified therapist easily and conveniently. The company was founded in 2020 and is based in Lagos, Nigeria.

WeVoice Logo

WeVoice provides digital solutions for mental health care. The company allows users to create a personalized emotional map, and accordingly receive appropriate meditative brain entertainment. It was founded in 2021 and is based in Malaga, Spain.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.